STOCK TITAN
  1. Home
  2. Sec-filings
  3. HIMS
  4. [Form 4] Hims & Hers Health, Inc. Insider Trading Activity

Hims & Hers (HIMS) director executed planned sale of 65,110 shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Andrew Dudum, a director, 10% owner and CEO-related reporting person of Hims & Hers Health, Inc. (HIMS), sold 65,110 shares of Class A common stock on 09/17/2025 under a Rule 10b5-1 trading plan adopted August 28, 2024. The sales generated an average weighted price of $50.5745 per share, with individual sale prices ranging from $50.06 to $50.94. After the reported transactions, the reporting person beneficially owned 95,315 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on 09/19/2025 and includes an undertaking to provide share-by-share price details upon request.

Positive

  • Transaction executed under a Rule 10b5-1 trading plan, indicating sales were pre-planned and non-discretionary
  • Filer committed to provide per-price sale details on request, demonstrating disclosure transparency
  • Form 4 was executed by an attorney-in-fact, showing formal execution and completion of filing requirements

Negative

  • Insider disposed of 65,110 shares, reducing beneficial ownership to 95,315 Class A shares
  • Average weighted sale price $50.5745 may reflect material cash proceeds depending on holder size (exact proceeds not summarized in document)

Insights

TL;DR: Routine insider sale under a pre-established 10b5-1 plan; no new derivative activity disclosed.

The reported 65,110-share disposition appears executed under a Rule 10b5-1 plan, which typically indicates pre-planned, non-discretionary sales rather than opportunistic trading. The average weighted sale price reported was $50.5745, with a disclosed price range of $50.06 to $50.94. Post-transaction beneficial ownership remains at 95,315 Class A shares, so the reporting person retains a meaningful stake. There are no derivative transactions reported on this Form 4.

TL;DR: Disclosure follows protocol; use of attorney-in-fact and 10b5-1 plan shows formal compliance.

The Form 4 discloses a planned sale under a 10b5-1 program adopted on August 28, 2024, and the filer included a commitment to provide detailed per-price quantities if requested. The signature by an attorney-in-fact is properly indicated. From a governance perspective, the filing demonstrates procedural compliance and transparent reporting of insider transactions, with no indicia on this filing of noncompliance or undisclosed related-party arrangements.

Insider Dudum Andrew
Role Chief Executive Officer
Sold 65,110 shs ($3.29M)
Type Security Shares Price Value
Sale Class A Common Stock 65,110 $50.5745 $3.29M
Holdings After Transaction: Class A Common Stock — 95,315 shares (Direct)
Footnotes (1)
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $50.06 - $50.94. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Dudum Andrew
(Last) (First) (Middle)
2269 CHESTNUT STREET, #523
(Street)
SAN FRANCISCO CA 94123
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 09/17/2025 S(1) 65,110 D $50.5745(2) 95,315 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
2. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $50.06 - $50.94. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Remarks:
/s/ Kimberly Mather, Attorney-in-Fact for Andrew Dudum 09/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Andrew Dudum report on the HIMS Form 4?

The filing reports the sale of 65,110 Class A shares on 09/17/2025 under a Rule 10b5-1 plan and a remaining beneficial ownership of 95,315 shares.

Was the sale by Andrew Dudum part of a 10b5-1 plan?

Yes. The Form 4 states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024.

At what price were the HIMS shares sold?

The average weighted price reported was $50.5745 per share, with individual sale prices ranging from $50.06 to $50.94.

How and when was the Form 4 signed?

The Form 4 was signed by Kimberly Mather, Attorney-in-Fact for Andrew Dudum on 09/19/2025.

Does the Form 4 show any derivative transactions for HIMS by the reporting person?

No. Table II (derivative securities) contains no reported transactions; only non-derivative Class A share sales are disclosed.